Trial intelligence / Profile preview

Cannabidiol for Co-occurring Opioid Use Disorder and Chronic Pain

NCT07886606Phase 1Recruiting

Sponsor
Yale University
Start
Dec 2021
Primary completion
Dec 2027
Countries
1
01

Overview

Phase 1, randomised trial of cannabidiol in opioid use disorder (OUD) and chronic pain (4 arms), sponsored by Yale University. Primary endpoints: Systematic Assessment for Treatment Emergent Effects, Drug Effects Questionnaire and 2 more. Started Dec 2021; status: recruiting.

02

Drugs

cannabidiol
03

Conditions

opioid use disorder (OUD)chronic pain

Beyond the preview

Go deeper on NCT07886606.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07886606.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call